Wed. Aug 10th, 2022

Hyderabad [Telangana], April 27: Dr. D. Srinivas Reddy, Chairman, and CEO of Optimus Pharma announced that they have filed for seeking emergency approval for Phase 3 Clinical Trial from the Drugs Controller General of India. Once the approval is granted for Phase 3 Clinical Trial, we would be extensively accelerating the manufacturing of our in-house developed generic version of Molnupiravir for making it available in the Indian market as soon as possible. Optimus Pharma is committed to halting the pandemic across the nation and ensuring immediate relief to all those who have been infected with the highly virulent SARS-CoV-2.

Optimus Pharma is pleased to announce the development of oral Molnupiravir on the fast lane. Optimus Pharma is becoming a key player in the fight against the COVID-19 pandemic in India has already achieved very high production levels of Favipiravir one of our flagship drugs for COVID-19 infection. In a bid to develop and diversify our anti-viral portfolio especially against SARS-CoV-2, we are here with yet another promising drug to compensate for the lack of antiviral drugs in the market further diversifying our antivirals portfolio. In hindsight of the raging second wave, Molnupiravir has been developed for non-hospitalized mild to moderate infections of SARS-CoV-2. Optimus Pharma is aggressively pushing for achieving scalability for 800mg dose of the drug.

Our available pre-clinical data on Molnupiravir already demonstrated that there were no adverse clinical signs and mortality observed in any of the treatment groups, as compared to the control group of animals with high efficacy and thereby effectively neutralizing virulence of the SARS-CoV-2 virus in the test group as compared to control group.

The drug is effective against a variety of viruses that use an RNA-dependent RNA polymerase (RdRp), as is the case with SARS-CoV-2 which is directly responsible for the transcription of Viral m-RNA of the virus in the infected subject. Early in vitro tests of Molnupiravir on SARS-CoV-2 revealed a steady decrease in virus output that was proportional to the dose of Molnupiravir used. Since the RdRp of SARS-CoV-2 and SARS-CoV, which the drug was designed to treat, has 99.1% nucleotide similarity hence, this was possible. Repeated drug exposure quickly neutralized virus populations, ensuring that none of the random mutations mediate drug resistance. As the drug is introduced in higher amounts, the titer levels and genome output of SARS-CoV-2 decrease exponentially.

It has been observed that Molnupiravir is only marginally successful in preventing extreme SARS-CoV-2 infection that is severe cases of the infection. This might have been the reason for their withdrawal and continue the trial only with non-hospitalized patients that are subjects with mild to moderate infection. We aim to do the same and establish its efficacy in the same treatment group.

Phase 2 Clinical Trial study on enrolled 202 non-hospitalized adults is already made available by the innovator of the molecule. Virological analysis was characterized by a marked decrease in positive viral culture in subjects who received Molnupiravir (all doses) relative to placebo – at day 5: 0% (0/47) for Molnupiravir and 24% (6/25) for placebo. Furthermore, the secondary objective for a faster decrease in infectious virus among people with early COVID-19 who were treated with Molnupiravir is encouraging and Phase 3 Clinical Trials are warranted for checking the efficacy of the molecule across demographics, particularly as the SARS-CoV-2 virus continues to spread and evolve globally.

Unlike the current drugs being administered intravenously, Molnupiravir is administered orally. This makes it a promising drug to halt the disease progression in the early stages as well as mount a powerful response against moderate infection levels. The fact that this molecule can be consumed as an orally administered drug in the form of an 800mg capsule renders a maverick advantage to achieve scalability in terms of upscaling from gm scale to multi-ton levels in a short time frame, thereby ensuring availability in the Indian market at a comparatively exponential scale. In vitro assays indicate that it is significantly more effective than the drugs being used currently, and the safety profile appears to be satisfactory.

By dsprime

17 thoughts on “Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India”
  1. Fine way of explaining, and fastidious piece of writing to take information on the topic of my
    presentation subject, which i am going to present in academy.

  2. Please let me know if you’re looking for a article author for
    your blog. You have some really good posts and I think I would be a good asset.
    If you ever want to take some of the load off, I’d really like to write some material for your blog in exchange for a link
    back to mine. Please send me an email if interested. Thank
    you!

  3. I am really enjoying the theme/design of your blog.

    Do you ever run into any web browser compatibility
    issues? A small number of my blog audience have complained about my site not operating correctly in Explorer but looks
    great in Opera. Do you have any tips to help fix this problem?

  4. You could certainly see your skills in the article you write.
    The sector hopes for more passionate writers such as you who aren’t afraid to mention how they believe.
    Always follow your heart.

  5. Thanks for your personal marvelous posting!

    I definitely enjoyed reading it, you might be a great author.
    I will remember to bookmark your blog and definitely will come back in the foreseeable future.
    I want to encourage you to definitely continue your great posts, have a nice holiday weekend!

  6. This design is incredible! You definitely know how to keep a reader amused.
    Between your wit and your videos, I was almost moved to start my own blog (well,
    almost…HaHa!) Excellent job. I really enjoyed what you had
    to say, and more than that, how you presented
    it. Too cool!

  7. Please let me know if you’re looking for a author for your blog.
    You have some really good articles and I believe I would be a good asset.
    If you ever want to take some of the load off, I’d really like to
    write some articles for your blog in exchange for a link back to mine.

    Please shoot me an e-mail if interested. Regards!

  8. I am sure this piece of writing has touched all the internet
    users, its really really nice article on building up
    new webpage.

  9. Howdy very nice blog!! Guy .. Beautiful .. Wonderful ..
    I will bookmark your website and take the feeds also?

    I’m happy to search out a lot of helpful information here within the
    submit, we need work out more strategies on this regard, thanks for sharing.
    . . . . .

  10. I’m really enjoying the design and layout of your website.
    It’s a very easy on the eyes which makes it much more enjoyable for me to come here
    and visit more often. Did you hire out a designer to create your theme?
    Exceptional work!

  11. An outstanding share! I’ve just forwarded this onto a colleague who had been doing a little research on this.
    And he actually bought me lunch because I stumbled upon it for him…
    lol. So allow me to reword this…. Thank YOU for the meal!!
    But yeah, thanks for spending time to talk about this issue here on your blog.

Leave a Reply

Your email address will not be published.